The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC): Cohort B of the phase 1b/2 KEYNOTE-365 study.
 
Christophe Massard
No Relationships to Disclose
 
Margitta Retz
No Relationships to Disclose
 
Peter Hammerer
Consulting or Advisory Role - Bayer; Janssen; Sanofi
 
Fernando Quevedo
No Relationships to Disclose
 
Peter C.C. Fong
Honoraria - AstraZeneca; Merck Sharp & Dome
Consulting or Advisory Role - Merck Sharp & Dome
Speakers' Bureau - Janssen
Travel, Accommodations, Expenses - Pfizer
 
William R. Berry
Honoraria - Bayer
Consulting or Advisory Role - Merck
Speakers' Bureau - Bayer
Research Funding - Merck
Travel, Accommodations, Expenses - Bayer; Merck
 
Howard Gurney
Honoraria - Pfizer
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Ipsen (Inst); Janssen-Cilag (Inst); Merck Sharp & Dohme (Inst)
 
Josep M. Piulats
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Clovis Oncology; Janssen Oncology; Merck Sharp & Dohme; Roche/Genentech; VCN Biosciences
Research Funding - AstraZeneca/MedImmune; Bristol-Myers Squibb; Incyte; Janssen Oncology; Merck Sharp & Dohme; Pfizer/EMD Serono
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Janssen Oncology; Roche
 
Anthony M. Joshua
Research Funding - Aptevo Therapeutics (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Lilly (Inst); Macrogenics (Inst); Mayne Pharma (Inst); Merck Sharp & Dohme (Inst); Roche/Genentech (Inst)
 
Mark David Linch
Consulting or Advisory Role - BioNTech; Bristol-Myers Squibb; Janssen
Research Funding - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Sanofi
Travel, Accommodations, Expenses - AstraZeneca; Janssen; Merck
 
Michael Paul Kolinsky
Honoraria - Janssen
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen; Merck
 
Emanuela Romano
Consulting or Advisory Role - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Roche/Genentech (Inst)
Research Funding - Bristol-Myers Squibb
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bristol-Myers Squibb; Roche
 
Srikala S. Sridhar
Consulting or Advisory Role - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); Merck (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Research Funding - Bayer (Inst); Janssen (Inst); Sanofi (Inst)
 
Henry Jacob Conter
Honoraria - Bristol-Myers Squibb; Celgene; Merck; Novartis
Consulting or Advisory Role - Lilly; Roche Canada
 
Marinela Augustin
Consulting or Advisory Role - Bristol-Myers Squibb; Ipsen; Lilly; Novartis; Pfizer; PharmaMar; Roche
Travel, Accommodations, Expenses - Ipsen; Lilly; Novartis; PharmaMar
 
Helen Wu
Employment - Merck Sharp & Dome
Stock and Other Ownership Interests - Bayer; Merck Sharp & Dome
 
Charles Schloss
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Christian Heinrich Poehlein
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Evan Y. Yu
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Churchill Pharmaceuticals; Dendreon; EMD Serono; Incyte; Janssen; Merck; QED Therapeutics; Seagen; Tolmar
Research Funding - Agensys (Inst); Astellas Pharma (Inst); Bayer (Inst); Dendreon (Inst); Genentech/Roche (Inst); Merck (Inst); Seagen (Inst)